Open Medicine Foundation

Open Medicine Foundation
Name	Open Medicine Foundation
Founded	0 2012
Type	501(c)(3)
Focus	Biomedical research
Headquarters	Agoura Hills, California
Key people	Linda Tannenbaum (Founder & CEO)
Website	https://www.omf.org

Open Medicine Foundation. It is a nonprofit biomedical research organization dedicated to accelerating research into complex chronic diseases, with a primary focus on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Founded in 2012, it operates on a collaborative, open-science model, funding centralized research centers and international projects aimed at discovering diagnostic biomarkers and effective treatments. The organization is known for its patient-centric approach and for assembling multidisciplinary teams of scientists from leading global institutions.

History and mission

The organization was established in 2012 by Linda Tannenbaum following her family's direct experience with the challenges of myalgic encephalomyelitis/chronic fatigue syndrome. Its founding mission was to address the critical lack of research funding and scientific understanding of ME/CFS and related complex diseases like Long COVID, fibromyalgia, and postural orthostatic tachycardia syndrome (POTS). The core philosophy emphasizes a collaborative, data-driven approach, aiming to break down traditional silos in academic research by fostering open data sharing among a global network of investigators. This model was designed to accelerate the path from fundamental discovery to clinical application for millions of patients worldwide.

Research focus and initiatives

Primary research is concentrated on identifying the underlying pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome, with major initiatives including the End ME/CFS Project and the Ramsay Research Fund. A flagship endeavor is the ME/CFS Collaborative Research Center at the Harvard-affiliated Harvard Medical School teaching hospitals, directed by W. Ian Lipkin and Mady Hornig. Research pillars include deep immunological profiling, metabolic dysfunction, neuroinflammation, and infectious disease triggers. Following the COVID-19 pandemic, it expanded its scope to include the study of Long COVID, establishing a dedicated research project to investigate overlaps with ME/CFS. Other key areas of investigation involve autonomic nervous system dysfunction and gut microbiome analysis.

Organizational structure and leadership

The organization is governed by a Board of Directors and led by its founder and Chief Executive Officer, Linda Tannenbaum. Its scientific strategy is guided by a prestigious Scientific Advisory Board that includes renowned researchers such as Ronald W. Davis of Stanford University, Jose Montoya of Stanford Health Care, and Anthony L. Komaroff of Brigham and Women's Hospital. Operations are supported by a team managing research administration, patient engagement, and fundraising. The structure is designed to be lean and efficient, directing the maximum proportion of funds to its research centers and grant programs, minimizing administrative overhead in line with its nonprofit status.

Funding and financials

It is funded primarily through philanthropic donations from individuals, family foundations, and community fundraising events. A public annual report details financials, consistently demonstrating that a high percentage of revenue is allocated directly to research programs and initiatives. It has received significant support from prominent donors and has been featured in media outlets like The New York Times and STAT News for its funding model. The organization does not accept funding from the pharmaceutical industry to maintain independence and focus on open, patient-driven science. Grants are awarded to its centralized research centers and to individual investigators through competitive peer-reviewed processes.

Key publications and findings

Researchers funded by the organization have authored numerous studies in high-impact journals, contributing seminal findings to the field. Notable publications have appeared in PNAS, Science Advances, and Cell Reports Medicine. Key findings include identification of distinct immunological signatures in patients, evidence of widespread metabolic disturbances, and data suggesting potential roles for herpesviruses like Epstein–Barr virus in disease mechanisms. Work led by Ronald W. Davis on a nanoneedle diagnostic assay has been widely reported. Studies from its Long COVID research project are also beginning to yield published data on shared biological pathways with ME/CFS.

Collaborations and partnerships

It maintains strategic collaborations with a global network of academic and clinical institutions. Major partners include the Stanford School of Medicine, the University of California, San Diego, the University of Melbourne, and the Charité hospital in Berlin. It also works closely with patient advocacy groups such as the Solve ME/CFS Initiative and the Bateman Horne Center to align research priorities. The organization is a founding member of the International Association of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFS/ME). These partnerships facilitate large-scale patient cohort studies, data sharing agreements, and multidisciplinary conferences to disseminate findings and coordinate international research efforts.

Category:Medical research organizations Category:Myalgic encephalomyelitis/chronic fatigue syndrome Category:Non-profit organizations based in California Category:Organizations established in 2012